Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 119

Results For "ALS"

7987 News Found

Regeneron signs $2.32 billion deal with Parabilis for Helicon conjugates
News | May 20, 2026

Regeneron signs $2.32 billion deal with Parabilis for Helicon conjugates

The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon peptide platform


Amita Patni appointed VP- Global Procurement Head at Shalina Healthcare
People | May 20, 2026

Amita Patni appointed VP- Global Procurement Head at Shalina Healthcare

She brings extensive expertise in managing global and domestic procurement operations


Philips unveils AI-powered SmartIQ to enhance coronary imaging
Medical Device | May 20, 2026

Philips unveils AI-powered SmartIQ to enhance coronary imaging

New CE-marked algorithm for the Azurion platform delivers improved image quality with over 50% lower radiation dose compared to the lowest settings on ClarityIQ


India committed to equitable healthcare: JP Nadda
Policy | May 20, 2026

India committed to equitable healthcare: JP Nadda

Union Health Minister highlights India’s progress in universal health coverage, digital health, AI strategy and global vaccine cooperation during plenary session in Geneva


Lupin gets tentative FDA nod for Revefenacin inhalation solution
Drug Approval | May 20, 2026

Lupin gets tentative FDA nod for Revefenacin inhalation solution

The drug is indicated for the maintenance treatment of patients with Chronic Obstructive Pulmonary Disease (COPD)


Bayer’s stroke drug wins fast-track review in US
Drug Approval | May 20, 2026

Bayer’s stroke drug wins fast-track review in US

The development comes as stroke remains one of the world’s biggest health threats


SN Bioscience doses first patient in global trial of experimental drug for aggressive lung cancer
Clinical Trials | May 19, 2026

SN Bioscience doses first patient in global trial of experimental drug for aggressive lung cancer

The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients


OrganaBio expands cell therapy manufacturing footprint with acquisition of Excellos Assets
Biotech | May 19, 2026

OrganaBio expands cell therapy manufacturing footprint with acquisition of Excellos Assets

The deal also establishes a new subsidiary, Excellos Labs, which will oversee continued operations in San Diego


MedGenome to expand integrated diagnostics access across Mumbai suburbs
Healthcare | May 19, 2026

MedGenome to expand integrated diagnostics access across Mumbai suburbs

Collaboration with Siddhi Diagnostics combines genomics and advanced imaging capabilities to strengthen precision diagnostics in high-growth suburban markets